Vitamin E intake reduces plasminogen activator inhibitor type 1 in T2DM patients

Citation
Ar. Bonfigli et al., Vitamin E intake reduces plasminogen activator inhibitor type 1 in T2DM patients, DIABET NUTR, 14(2), 2001, pp. 71-77
Citations number
44
Categorie Soggetti
Endocrynology, Metabolism & Nutrition
Journal title
DIABETES NUTRITION & METABOLISM
ISSN journal
03943402 → ACNP
Volume
14
Issue
2
Year of publication
2001
Pages
71 - 77
Database
ISI
SICI code
0394-3402(200104)14:2<71:VEIRPA>2.0.ZU;2-P
Abstract
Previous studies hypothesised that vitamin E could protect against coronary heart disease and vascular complications in diabetes, but no studies have been performed regarding its eventual effects on fibrinolysis. Nevertheless , in Type 2 diabetes mellitus (T2DM) a profound reduction in the fibrinolyt ic activity has been demonstrated to be involved in vascular complications, probably due to plasminogen activator inhibitor type 1 (PAI-1) overproduct ion. On this basis we aimed to verify whether an antioxidant treatment with vitamin E is able to lower PAI-1 plasma levels in T2DM, Thirteen T2DM pati ents (9 males and 4 females; mean age +/- SD, 64.4 +/-3.3 yr) were selected through strict admission criteria. These patients were treated with vitami n E (500 IU/die) for 10 weeks. Glyco-lipometabolic, oxidative and haemocoag ulative parameters were evaluated at baseline and after 5, 10, 30 and 60 we eks. Vitamin E levels at different times were [median (interquartile range) ] 6.1 (5.3-7.7), 8.5 (7.3-9.9), 9.7 (8,9-12,9), 5.6 (4.4-6.8), 5.7 (4.5-7.1 ) mug/ml, respectively. Significant differences were found for PAI-1 antige n (p=0.006), PAI-1 activity (p=0.028), apolipoprotein B (p=0.015) and antio xidant defence, evaluated as ferric reducing ability of plasma (FRAP) value s (p=0.005). Particularly, decrements were detected for PAI-1 antigen betwe en baseline and the 10(th) week (p <0.05), followed by an increase back to basal at the 30(th) week. Similar behaviour was found for PAI-1 activity. R egarding the antioxidant defence, FRAP values increased until the 30(th) we ek (p <0.05) with a decrease at the 60(th) week. These results demonstrate that vitamin E is able to lower PAI-1 levels in diabetic patients but this effect does not seem related to improvements of glycometabolic data or to t he increase in FRAP values, suggesting that PAI-1 overproduction can be dec reased by other effects of vitamin E on endothelial cells. (C) 2001. Editri ce Kurtis.